Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15369081 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL11498283 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL13983301 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL25366902 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL25366224 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL25365258 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL24268977 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL25365949 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL9707061 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 | |
| SCHEMBL109477 | 0.98 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD. AT BEN-GURION UNIVERSITY (IL) | 2024-04-04 | — | — | US | disclosed |
| EP-4277896-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022153306-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-07-21 | — | — | WO | disclosed |
| EP-3950691-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR | Daewoong Pharmaceutical Co., Ltd. (KR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210363126-A1 | PROCESS FOR THE PREPARATION OF PIPERINE | CIPLA LIMITED (IN) | 2021-11-25 | — | — | US | disclosed |
| EP-3808743-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | Janssen Pharmaceutica NV (BE) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020243457-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC (US) | 2020-12-03 | — | — | WO | disclosed |
| US-20200316731-A1 | NUTRITIONAL SUPPLEMENT FOR INCREASING COGNITIVE FUNCTIONS | INNOVUS PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | US | disclosed |
| CN-111615511-A | Process for preparing piperine | 西普拉有限公司 | 2020-09-01 | — | — | CN | disclosed |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | HUTCHINSON ALAN J (US) | 2011-11-17 | — | — | US | disclosed |
| US-7863454-B2 | 3-substituted-6-aryl pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-01-04 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-07-09 | — | — | US | disclosed |
| US-7342115-B2 | Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology | NEUROGEN CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | FPR1, FPR2, IL1B | ALDH1A1 2719/4885MAPT 3720/4885SMN1; SMN2 4845/4885 |
| US-20110281837-A1 | 3-SUBSTITUTED-6-ARYL PYRIDINES | C3AR1, C5AR1, C5AR2 | ALDH1A1 1966/4885MAPT 4726/4885SMN1; SMN2 4559/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | ALDH1A1 188/4885MAPT 3887/4885SMN1; SMN2 3722/4885 |
| US-20090176980-A1 | 3-Substituted-6-Aryl Pyridines | C3AR1, C5AR1, C5AR2 | ALDH1A1 1966/4885MAPT 4726/4885SMN1; SMN2 4559/4885 |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | ALDH1A1 3445/4885MAPT 4242/4885SMN1; SMN2 4101/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | ALDH1A1 2133/4885MAPT 989/4885SMN1; SMN2 3562/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | ALDH1A1 1723/4885MAPT 4688/4885SMN1; SMN2 4522/4885 |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | ALDH1A1 2831/4885MAPT 3275/4885SMN1; SMN2 2932/4885 |
| US-20210363126-A1 | PROCESS FOR THE PREPARATION OF PIPERINE | PTMA, ITPA, PRPH | ALDH1A1 407/4885MAPT 2856/4885SMN1; SMN2 648/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | ALDH1A1 2657/4885MAPT 4703/4885SMN1; SMN2 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.